BCM
CRL icon

Buckhead Capital Management’s Charles River Laboratories CRL Stock Holding History

Buckhead Capital Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-18,487
Closed -$2.78M – 129
2025
Q1 		$2.78M Sell
18,487
-662
-3% -$111K 0.89% 46
2024
Q4 		$3.53M Sell
19,149
-1,961
-9% -$378K 1.13% 40
2024
Q3 		$4.16M Sell
21,110
-221
-1% -$45.9K 1.31% 30
2024
Q2 		$4.41M Buy
21,331
+779
+4% +$177K 1.49% 26
2024
Q1 		$5.57M Buy
20,552
+409
+2% +$97.7K 1.88% 13
2023
Q4 		$4.76M Buy
20,143
+901
+5% +$177K 1.76% 16
2023
Q3 		$3.77M Buy
19,242
+1,820
+10% +$374K 1.57% 25
2023
Q2 		$3.66M Sell
17,422
-2,667
-13% -$531K 0.87% 41
2023
Q1 		$4.05M Buy
20,089
+1,703
+9% +$386K 0.95% 40
2022
Q4 		$4.01M Buy
18,386
+4,698
+34% +$1.03M 0.97% 42
2022
Q3 		$2.69M Buy
13,688
+6,438
+89% +$1.39M 0.7% 50
2022
Q2 		$1.55M Buy
+7,250
New +$1.77M 0.38% 71

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Buckhead Capital Management's CRL Position: Q2 2025 in Review

Buckhead Capital Management sold out of Charles River Laboratories (CRL) in Q2 2025, closing a stake of 18,487 shares — an estimated $2.78M sold.

Buckhead Capital Management first reported a position in CRL in Q2 2022 and held it in 12 quarters. The position peaked at $5.57M in Q1 2024. 519 funds tracked by Wall St. Rank hold CRL as of Q2 2025.

  • Buckhead Capital Management reported no remaining Charles River Laboratories position as of Q2 2025 after selling out during the quarter.
  • Buckhead Capital Management sold 18,487 Charles River Laboratories shares in Q2 2025, an estimated $2.78M.
  • Buckhead Capital Management first reported a position in Charles River Laboratories in Q2 2022 and held it in 12 quarters.
  • Buckhead Capital Management's Charles River Laboratories position peaked at $5.57M in Q1 2024.
  • 519 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2025.

Based on Buckhead Capital Management's 13F filing for Q2 2025, filed 4 Aug 2025.